Roche ends 2 Huntington’s disease programs, including Ionis-partnered tominersen
Roche has halted development on two of its Huntington’s disease prospects, marking another blow for a patient community that has long awaited new medicines.
Read the full articleYou might also wanna read
AstraZeneca’s Wainua fails main goal in late-stage heart disease trial
Drug developed with Ionis could not reduce cardiovascular deaths or recurring heart problems
FDA reconsidering gene therapy for Huntington's disease after official who rejected it leaves agency
Gene therapy company UniQure had another FDA meeting after Vinay Prasad's exit.
arstechnica.com·22d ago
STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drug
Huntington's disease treatment shows success in slowing progression for first time, UK trial finds
One of the most devastating diseases finally has a treatment that can slow its progression and transform lives, tearful doctors tell BBC.
bbc.com·9mo agoDividenden-Garant Astrazeneca im freien Fall: Studien-Flop schockt Anleger
Nackenschlag für den britisch-schwedischen Pharma-Konzern Astrazeneca und den Entwicklungspartner Ionis Pharmaceuticals. Der Hoffnungsträger
Roche Aktie: Neue Alzheimer-Daten im Juli
Roche geht einen ungewöhnlichen Weg in der Alzheimer-Forschung. Der Schweizer Pharmakonzern verknüpft seine Diagnostik-Sparte mit der Entwic
Comments
Sign in to join the conversation.
No comments yet. Be the first.